Risk of Ventricular Arrhythmia and Sudden Cardiac Death Associated with Combined Use of Antipsychotics and SSRIs - Takeaways - MDSpire

Risk of Ventricular Arrhythmia and Sudden Cardiac Death Associated with Combined Use of Antipsychotics and SSRIs

  • By

  • Hsiu-Ting Chien

  • Shu-Wen Lin

  • Te-Jung Kung

  • Chi-Chuan Wang

  • Yaa-Hui Dong

  • Tzung-Jeng Hwang

  • Fang-Ju Lin

  • Sengwee Toh

  • April 9, 2026

  • 0 min

Share

  • 1

    Medication-related ventricular arrhythmia and sudden death are rare but serious risks associated with antipsychotics and SSRIs.

  • 2

    Antipsychotics consistently show higher rates of sudden death compared to nonuse, while evidence for SSRIs is mixed.

  • 3

    Concurrent use of antipsychotics and SSRIs is common, despite concerns about drug-drug interactions that may increase arrhythmia risk.

  • 4

    The study utilized large insurance claims databases to estimate the risk of ventricular arrhythmia or sudden death following SSRI initiation.

  • 5

    Findings indicate that the clinical impact of combined antipsychotic and SSRI use on arrhythmic outcomes remains uncertain.

Original Source(s)

Risk of Ventricular Arrhythmia and Sudden Cardiac Death Associated with Combined Use of Antipsychotics and SSRIs

  • by Hsiu-Ting Chien, Shu-Wen Lin, Te-Jung Kung, Chi-Chuan Wang, Yaa-Hui Dong, Tzung-Jeng Hwang, Fang-Ju Lin, Sengwee Toh

  • April 9, 2026

Related Content

Postoperative Step Counts Tied to Surgical Recovery

Wearable-measured mobility—but not heart rate variability or wellness scores—was associated with length of stay, complications, and readmissions

Top 10 States for Physician-Owned Hospitals

These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.